These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33225963)

  • 1. A novel human laboratory model for screening medications for alcohol use disorder.
    Ho D; Towns B; Grodin EN; Ray LA
    Trials; 2020 Nov; 21(1):947. PubMed ID: 33225963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial.
    Ray LA; Baskerville WA; Nieto SJ; Grodin E; Enders C; Kady A; Meredith L; Gillis A; Leventhal A; Ho D; Miotto K
    Psychopharmacology (Berl); 2024 Mar; 241(3):543-553. PubMed ID: 38012333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial.
    Burnette EM; Baskerville WA; Grodin EN; Ray LA
    Trials; 2020 Sep; 21(1):779. PubMed ID: 32912290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
    Nieto SJ; Enders CK; Witkiewitz K; O'Malley SS; Ray LA
    Alcohol Clin Exp Res; 2022 Dec; 46(12):2258-2266. PubMed ID: 36515648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing reward and relief/habit drinking profiles in a study of naltrexone, varenicline, and placebo.
    Kady A; Grodin EN; Ray LA
    Alcohol Alcohol; 2024 May; 59(4):. PubMed ID: 38953743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
    Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
    JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.
    Miranda R; O'Malley SS; Treloar Padovano H; Wu R; Falk DE; Ryan ML; Fertig JB; Chun TH; Muvvala SB; Litten RZ
    Alcohol Clin Exp Res; 2020 Jul; 44(7):1431-1443. PubMed ID: 32363592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leveraging meta-regression to test if medication effects on cue-induced craving are associated with clinical efficacy.
    Nieto SJ; Du H; Meredith LR; Donato S; Magill M; Ray LA
    Psychopharmacology (Berl); 2024 Aug; 241(8):1679-1689. PubMed ID: 38613685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study.
    Roberts W; Shi JM; Tetrault JM; McKee SA
    J Addict Med; 2018; 12(3):227-233. PubMed ID: 29438157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-regression of methodological features that predict the effects of medications on the subjective response to alcohol.
    Green R; Du H; Grodin EN; Nieto SJ; Bujarski S; Roche DJO; Ray LA
    Alcohol Clin Exp Res; 2021 Jul; 45(7):1336-1347. PubMed ID: 34120356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol use disorder severity moderates clinical response to varenicline.
    Donato S; Green R; Ray LA
    Alcohol Clin Exp Res; 2021 Sep; 45(9):1877-1887. PubMed ID: 34486130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder.
    Belnap MA; McManus KR; Grodin EN; Ray LA
    Pharmaceut Med; 2024 Jul; 38(4):291-302. PubMed ID: 38967906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of sleep quality on lapse to alcohol use during a quit attempt.
    Baskerville WA; Grodin EN; Ray LA
    Alcohol Alcohol; 2024 Jan; 59(2):. PubMed ID: 38366914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do behavioral pharmacology findings predict clinical trial outcomes? A proof-of-concept in medication development for alcohol use disorder.
    Ray LA; Du H; Green R; Roche DJO; Bujarski S
    Neuropsychopharmacology; 2021 Feb; 46(3):519-527. PubMed ID: 33235284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers.
    Grodin EN; Burnette EM; Green R; Lim AC; Miotto K; Ray LA
    Drug Alcohol Depend; 2021 Aug; 225():108825. PubMed ID: 34175784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are medication effects on subjective response to alcohol and cue-induced craving associated? A meta regression study.
    Ray LA; Nieto SJ; Meredith LR; Burnette E; Donato S; Magill M; Du H
    Psychopharmacology (Berl); 2023 Sep; 240(9):1921-1930. PubMed ID: 37452887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing pharmacotherapies for alcohol use disorder with cue exposure paradigms: A systematic review and quantitative synthesis of human laboratory trial methodology.
    Meredith LR; Burnette EM; Nieto SJ; Du H; Donato S; Grodin EN; Green R; Magill M; Baskerville WA; Ray LA
    Alcohol Clin Exp Res (Hoboken); 2023 Sep; 47(9):1629-1645. PubMed ID: 37423771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing alcohol cue reactive and non-reactive individuals with alcohol use disorder.
    Kirsch DE; Grodin EN; Ray LA
    Addict Behav; 2024 Aug; 155():108028. PubMed ID: 38640885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapies and personalized medicine for alcohol use disorder: a review.
    Lohoff FW
    Pharmacogenomics; 2020 Oct; 21(15):1117-1138. PubMed ID: 32807012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming the "Valley of Death" in Medications Development for Alcohol Use Disorder.
    Ray LA; Bujarski S; Roche DJO; Magill M
    Alcohol Clin Exp Res; 2018 Sep; 42(9):1612-1622. PubMed ID: 29969156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.